Overview

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Treatments:
Olmesartan
Olmesartan Medoxomil